Interestingly, in a recent study of advanced RCC patients (n = 85), focused on measuring circulating levels of three pro-angiogenic cytokines (IL-6, bFGF, and HGF), progression on sunitinib was preceded by increases in circulating levels of all three markers [24]. This evidence concerns the gene HGF and renal cell carcinoma.